Animal diseases

Bio-Rad Launches Its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit for COVID-19 Wastewater Testing

Retrieved on: 
Monday, June 21, 2021
Health, Infectious diseases, Utilities, Other Health, Energy, Biotechnology, Sarbecovirus, Zoonoses, Animal diseases, Branches of biology, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Real-time polymerase chain reaction, Wastewater-based epidemiology

ddPCR technology is recommended in the Centers for Disease Control and Prevention guidelines (CDC) for wastewater testing, and use of the technology has been published by the Environmental Protection Agency (EPA) as a dependable method to quantify viruses in wastewater.

Key Points: 
  • ddPCR technology is recommended in the Centers for Disease Control and Prevention guidelines (CDC) for wastewater testing, and use of the technology has been published by the Environmental Protection Agency (EPA) as a dependable method to quantify viruses in wastewater.
  • The PREvalenceddPCR SARS-CoV-2 Wastewater Quantification Kit includes all reagents needed to detect the virus in wastewater along with software for automated analysis.
  • Other products include molecular qPCR and ddPCR instruments and assays, antibody tests, quality controls, and ddPCRassays to detect SARS-CoV-2 variants of concern.
  • BIO-RAD, PREVALENCE, DROPLET DIGITAL, DDPCR, QX200, AUTODG and QX ONE are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

PERFORMACIDE® Kills Virus Causing COVID-19 In Just 30 Seconds

Retrieved on: 
Tuesday, June 22, 2021
Sarbecovirus, Respiratory diseases, Animal diseases, Medical specialties, Zoonoses, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Disinfectant

Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.

Key Points: 
  • Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.
  • To prove efficacy, PERFORMACIDE was tested directly against the SARS-CoV-2 (COVID-19) virus.
  • CEO and President, Peter Dornau, commented, "Killing the virus that causes COVID-19 in under a minute will dramatically expand the markets for PERFORMACIDE and its sub-registered brands.
  • Mr. Dornau concluded, "PERFORMACIDE already reduces the many steps involved in a full cleaning routine by eliminating rinsing or wiping again.

Clean Republic Announces SARS-CoV-2 (Covid-19 Virus) 60-Second Kill Claim

Retrieved on: 
Thursday, June 17, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Bactericides, Disinfectant, Hygiene, Animal diseases, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

The announcement comes after testing and resubmission to the EPA and replaces the prior 10-minute kill claim.

Key Points: 
  • The announcement comes after testing and resubmission to the EPA and replaces the prior 10-minute kill claim.
  • At 60 seconds, the Clean Republic Disinfectant + Sanitizer is now one of the fastest acting products on the market for use against SARS-CoV-2.
  • At 60 seconds, Clean Republic Disinfectant + Sanitizer is one of the fastest acting products for use against SARS-CoV-2.
  • "We are proud of the work of our innovations team and this milestone claim from the EPA," said Jake Piccoli, Co-founder and President of Clean Republic.

Two Days Left to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC

Retrieved on: 
Thursday, June 17, 2021
Legal, Professional services, Sarbecovirus, Animal diseases, Health, Directorate-General for Health and Food Safety, Severe acute respiratory syndrome coronavirus 2, European Centre for Disease Prevention and Control, Severe acute respiratory syndrome

Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/ebs .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/ebs .
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
  • or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in Emergent you have until June 18, 2021 to request that the Court appoint you as lead plaintiff.

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

Retrieved on: 
Tuesday, June 15, 2021
Sarbecovirus, Respiratory diseases, Medical specialties, Animal diseases, COVID-19, Occupational safety and health, Public health, Zoonoses, Severe acute respiratory syndrome, Antiviral drug, TLR2

The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.

Key Points: 
  • The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
  • The milestone-based financing round was jointly led by Australian life science investors Brandon Capital Partners and Minderoo Foundation, with co-investment from Uniseed.
  • We recognize that in addition to vaccines, the world needs safe, convenient, broad-spectrum anti-viral therapies to win the fight against COVID-19, said Chris Smith, Ph.D., Chairman of ENA Respiratory.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

2021 Recipient of the Canadian Animal Health Institute’s Industry Leadership Award

Retrieved on: 
Monday, June 14, 2021
Veterinary medicine, Health sciences, Food and drink, Veterinary drugs, Food politics, Animal diseases, Agriculture in Canada, Canadian Food Inspection Agency, Meat inspection, Chief Veterinary Officer, Veterinary biologic, Veterinarian

GUELPH, Ontario, June 14, 2021 (GLOBE NEWSWIRE) -- Dr. Mary Jane Ireland, Executive Director of the Animal Health Directorate and Deputy Chief Veterinary Officer at the Canadian Food Inspection Agency (CFIA), was presented with the Canadian Animal Health Institutes (CAHI) Industry Leadership Award at its Annual General Meeting on June 10th, 2021.

Key Points: 
  • GUELPH, Ontario, June 14, 2021 (GLOBE NEWSWIRE) -- Dr. Mary Jane Ireland, Executive Director of the Animal Health Directorate and Deputy Chief Veterinary Officer at the Canadian Food Inspection Agency (CFIA), was presented with the Canadian Animal Health Institutes (CAHI) Industry Leadership Award at its Annual General Meeting on June 10th, 2021.
  • This award recognizes key contributors to animal health in Canada who work tirelessly to enhance the health of our pets and livestock.
  • CAHI is pleased to award Mary Jane with its Industry Leadership award as her commitment to animal health is undeniable.
  • The Animal Health Directorate at the Canadian Food Inspection Agency addresses a diverse portfolio of responsibilities related to terrestrial and aquatic animal health, animal pathogens, livestock feed, veterinary biologics.

Insights on the Rabies Diagnostics Global Market to 2027 - Featuring Abbexa, BioNote and Creative Diagnostics Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021
Health, Pets, Consumer, Medical devices, Medical specialties, Infectious diseases, Animal diseases, Rabies, Viral encephalitis, Zoonoses

The "Rabies Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rabies Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Rabies Diagnostics estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.1 Billion by 2027, growing at a CAGR of 4% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $432 Million, While China is Forecast to Grow at 6.4% CAGR
    The Rabies Diagnostics market in the U.S. is estimated at US$432 Million in the year 2020.
  • In the global Amplification Methods segment, USA, Canada, Japan, China and Europe will drive the 4.3% CAGR estimated for this segment.

NYU Langone Health to Co-Lead NIH-funded Effort to Understand Long-term Effects of SARS-CoV-2 Infection

Retrieved on: 
Thursday, June 10, 2021
Coronaviridae, Sarbecovirus, Respiratory diseases, Animal diseases, COVID-19, Long Covid, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, PASC, NYU Langone Health

NEW YORK, June 10, 2021 /PRNewswire/ -- NYU Langone Health has been selected as the Clinical Science Core (CSC) for the National Institutes of Health's PASC (Post-Acute Sequelae of SARS-CoV-2 Infection) Initiative.

Key Points: 
  • NEW YORK, June 10, 2021 /PRNewswire/ -- NYU Langone Health has been selected as the Clinical Science Core (CSC) for the National Institutes of Health's PASC (Post-Acute Sequelae of SARS-CoV-2 Infection) Initiative.
  • Congress provided $1.15 billion in funding over four years for NIH to support research into the prolonged health consequences of SARS-CoV-2 infection in December of 2020.
  • How many people continue to have symptoms of COVID-19, or even develop new symptoms, after acute SARS-CoV-2 infection?
  • The PASC CSC at NYU Langone Health (NIH funding no.

Selva Announces SLV213, a Potential Oral COVID-19 Treatment, Has Broad Activity Against SARS-CoV-2 Variants of Concern

Retrieved on: 
Wednesday, June 9, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Hospitals, Clinical trials, Respiratory diseases, Animal diseases, Health, Antiviral drug, Biocides, COVID-19, Severe acute respiratory syndrome

No loss of potency was found and equal activity against all variants was determined, explained Felix Frueh, Ph.D., Chief Scientific Officer of Selva.

Key Points: 
  • No loss of potency was found and equal activity against all variants was determined, explained Felix Frueh, Ph.D., Chief Scientific Officer of Selva.
  • SLV213 has demonstrated activity against SARS-CoV-2 in vitro and in vivo and completed a Phase 1 clinical trial for safety.
  • As an oral antiviral, SLV213 has the potential to fill a critical gap in the treatment landscape for COVID-19.
  • Selva previously reported that SLV213 successfully completed a Phase 1 ascending oral dose clinical trial in healthy subjects.

Thermo Fisher Scientific Launches Ion AmpliSeq SARS-CoV-2 Insight Research Assay for SARS-CoV-2 Surveillance

Retrieved on: 
Monday, June 7, 2021
Sarbecovirus, Zoonoses, Animal diseases, Infectious diseases, Thermo Fisher Scientific, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

CARLSBAD, Calif., June 7, 2021 /PRNewswire/ --Thermo Fisher Scientific today introduced the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to improve SARS-CoV-2 surveillance.

Key Points: 
  • CARLSBAD, Calif., June 7, 2021 /PRNewswire/ --Thermo Fisher Scientific today introduced the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to improve SARS-CoV-2 surveillance.
  • The new Ion AmpliSeq SARS-CoV-2 Insight Research Assay broadens and improves local, regional and national surveillance efforts to discover emerging SARS-CoV-2 variants through highly sensitive next-generation sequencing (NGS).
  • To further expedite NGS analysis of SARS-CoV-2 and to help meet growing customer demand,Thermo Fisherhas begun optimizing the Ion AmpliSeq SARS-CoV-2 Insight Research Assay for the Ion Torrent Genexus System .
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.